GlaxoSmithKline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)1,324.75
  • Today's Change49.05 / 3.84%
  • Shares traded48.86k
  • 1 Year change-19.82%
  • Beta0.5318
Data delayed at least 15 minutes, as of Mar 31 2023 11:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in the business of manufacturing, distributing, and trading in pharmaceuticals. It manufactures medicinal substances used in the manufacture of pharmaceuticals, such as antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts, and esters; glycosides and vegetable alkaloids, and chemically pure sugar. It offers a range of prescription medicines, vaccines, and consumer healthcare products. Its medicine portfolio includes Adartrel, Bactroban, Combodart, and Duodart. Its vaccines portfolio includes Ambirix, Cervarix, Fendrix, and Havrix. The Company’s products include Betamethasone, Potassium Clavulanate with Amoxycillin and Pneumococcal Polysaccharide and Conjugate Vaccine. Its oral health products include Sensodyne, parodontax and Polident. Its manufacturing unit is located at Nashik.

  • Revenue in INR (TTM)32.74bn
  • Net income in INR4.20bn
  • Incorporated1924
  • Employees3.84k
  • Location
    GlaxoSmithKline Pharmaceuticals LtdDr Annie Besant Road, WorliMUMBAI 400030IndiaIND
  • Phone+91 2 224959595
  • Fax+91 2 224981526
  • Websitehttp://india-pharma.gsk.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Suven Pharmaceuticals Ltd13.35bn3.79bn120.23bn1.19k31.75--28.289.0114.8814.8852.40--------11,188,770.00--------56.31--28.39----95.61----30.75--25.24------
Glenmark Pharmaceuticals Ltd126.36bn8.81bn125.69bn15.42k14.27--8.110.994831.2231.22447.75--------8,196,914.00--6.23--8.5865.3760.287.548.40--5.25--7.6612.446.02-2.930.55591.094.56
Sanofi India Ltd27.70bn6.21bn129.29bn2.51k20.8310.1319.514.67269.47269.471,202.82553.961.082.9720.37--24.1819.3934.0825.3457.0656.3822.4019.611.62389.710.018256.01-6.312.14-34.2913.74-17.1922.27
J B Chemicals and Pharmaceuticals Ltd30.12bn4.07bn151.25bn4.34k37.38--29.545.0252.2952.29386.99--------6,939,050.00--14.74--17.4763.2759.8313.5315.46--23.30--29.5718.6912.20-13.9815.9335.2575.18
Ajanta Pharma Ltd37.31bn6.17bn154.90bn7.23k25.18--20.774.1548.0148.01290.34--------5,157,714.00--17.70--21.0771.8975.7016.5420.68------15.3515.6210.798.997.05-13.03-6.08
Piramal Enterprises Ltd104.23bn102.74bn157.95bn13.56k1.55--1.491.52430.44430.44436.59--------7,686,321.00--2.44--3.4062.8082.3598.9615.05--1.45--30.489.2410.3644.348.96-15.0910.12
Laurus Labs Ltd60.84bn9.18bn160.01bn5.13k17.45--13.072.6317.0217.02112.84--------11,858,270.00--11.29--19.6554.5947.9515.1413.77--9.94--11.742.5420.64-15.8734.1825.8746.14
Pfizer Limited24.02bn6.20bn160.24bn2.29k25.85--21.916.67135.52135.52524.87--------10,511,070.00--12.76--16.5364.7260.6825.8221.77--46.21--84.0516.645.0423.1012.71-9.5518.47
IPCA Laboratories Ltd60.22bn5.25bn199.53bn15.16k38.01--25.073.3120.6920.69237.30--------3,973,468.00--12.86--16.6664.4459.869.0114.45--18.13--10.267.5612.67-22.4535.3628.5751.57
Gland Pharma Ltd39.43bn9.89bn207.16bn4.64k20.99--18.355.2559.9159.91239.01--------8,498,823.00--------52.67--25.07----146.39----27.08--21.54------
GlaxoSmithKline Pharmaceuticals Limited32.74bn4.20bn216.11bn3.84k51.51--44.716.6024.76100.12193.23--------8,525,779.00--8.78--13.9560.5553.7312.8110.19--519.35--212.5312.051.7932.552.48-35.2514.87
Syngene International Ltd29.57bn4.33bn231.31bn5.98k53.11--29.487.8210.9010.9074.13--------4,948,285.00--9.20--12.6673.5870.6314.6618.41--7.95----19.2216.74-2.256.629.190.00
Biocon Ltd98.09bn3.88bn240.64bn3.20k62.29--16.332.453.243.2481.89--------30,624,730.00--5.67--7.8666.7460.435.2212.71--3.17--5.2314.5715.85-12.441.1620.360.00
Lupin Ltd160.95bn-3.24bn296.83bn19.79k----46.551.84-7.15-7.15353.59--------8,133,110.00--0.0772--0.108158.6161.21-1.900.1267--5.03--2,376.128.19-1.28-225.61---19.25-11.81
Aurobindo Pharma Ltd241.92bn19.98bn298.62bn21.00k14.95--9.481.2334.0934.09412.78--------11,519,900.00--11.53--18.3055.0053.958.2614.54--39.07--6.66-5.329.22-50.362.849.8129.20
Data as of Mar 31 2023. Currency figures normalised to GlaxoSmithKline Pharmaceuticals Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

14.28%Per cent of shares held by top holders
HolderShares% Held
Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 20227.01m4.14%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 28 Feb 20232.98m1.76%
BlackRock Investment Management (UK) Ltd.as of 28 Feb 20232.97m1.75%
Newton Investment Management Ltd.as of 31 Dec 20212.60m1.54%
ICICI Prudential Asset Management Co. Ltd.as of 28 Feb 20232.53m1.49%
General Insurance Corp. of India (Invt Port)as of 30 Sep 20222.40m1.42%
The Vanguard Group, Inc.as of 03 Mar 20231.27m0.75%
Aditya Birla Sun Life Insurance Co. Ltd.as of 28 Feb 20231.19m0.70%
SBI Funds Management Pvt Ltd.as of 28 Feb 2023810.04k0.48%
BlackRock Fund Advisorsas of 01 Mar 2023428.76k0.25%
More ▼
Data from 31 Dec 2022 - 14 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.